Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079348 | 0.97 | ALK (0.33) | MAPK1MAPKAPK2ALKKDR | |
| SCHEMBL31079041 | 0.97 | ALK (0.34) | MAPK1MAPKAPK2ALKKDRCDC7 | |
| SCHEMBL31079216 | 0.92 | MAPK1 (0.40) | MAPK1MAPKAPK2ALK | |
| SCHEMBL29964555 | 0.90 | CDK4 (0.37) | MAPK1MAPKAPK2FEN1CD274 | |
| SCHEMBL29964362 | 0.89 | MAPK1 (0.39) | MAPK1MAPKAPK2ALKKDR | |
| SCHEMBL29965127 | 0.89 | MAPK1 (0.39) | MAPK1MAPKAPK2ALKKDRCDC7 | |
| SCHEMBL31078997 | 0.89 | MAPKAPK2 (0.33) | MAPKAPK2CD274 | |
| SCHEMBL31079254 | 0.89 | MAPK1 (0.36) | MAPK1MAPKAPK2ALOX5APFEN1CD274 | |
| SCHEMBL31079364 | 0.88 | PIK3CD (0.33) | MAPKAPK2ALOX5APFEN1CD274 | |
| SCHEMBL31079433 | 0.86 | PDE3B (0.35) | MAPK1MAPKAPK2ALOX5APFEN1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | MAPK1 141/4885MAPKAPK2 79/4885ALOX5AP 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.